Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model
出版年份 2017 全文链接
标题
Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model
作者
关键词
-
出版物
OncoImmunology
Volume 6, Issue 8, Pages e1338236
出版商
Informa UK Limited
发表日期
2017-06-16
DOI
10.1080/2162402x.2017.1338236
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A novel rat fibrosarcoma cell line from transformed bone marrow-derived mesenchymal stem cells with maintained in vitro and in vivo stemness properties
- (2017) Meng-Yu Wang et al. EXPERIMENTAL CELL RESEARCH
- LTX-315, CAPtivating immunity with necrosis
- (2016) Antonella Sistigu et al. CELL CYCLE
- The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade
- (2016) T Yamazaki et al. CELL DEATH AND DIFFERENTIATION
- Can immunostimulatory agents enhance the abscopal effect of radiotherapy?
- (2016) Antonin Levy et al. EUROPEAN JOURNAL OF CANCER
- Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide
- (2016) Bengt Erik Haug et al. JOURNAL OF MEDICINAL CHEMISTRY
- The oncolytic peptide LTX-315 triggers immunogenic cell death
- (2016) H Zhou et al. Cell Death & Disease
- Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking?
- (2016) Sandra Demaria et al. Journal for ImmunoTherapy of Cancer
- The oncolytic peptide LTX-315 triggers necrotic cell death
- (2015) Sabrina Forveille et al. CELL CYCLE
- Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches
- (2015) Qin Pan et al. STEM CELLS
- The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization
- (2015) Heng Zhou et al. Oncotarget
- Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
- (2015) Bin Shang et al. Scientific Reports
- Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315
- (2014) Ketil André Camilio et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- LTX-315 (Oncopore™)
- (2014) Ketil André Camilio et al. OncoImmunology
- Consensus guidelines for the detection of immunogenic cell death
- (2014) Oliver Kepp et al. OncoImmunology
- Cancer Stem Cells and Their Mechanism of Chemo-Radiation Resistance
- (2014) Yonghyun Kim et al. International Journal of Stem Cells
- Understanding and targeting cancer stem cells: therapeutic implications and challenges
- (2013) Ke Chen et al. ACTA PHARMACOLOGICA SINICA
- Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
- (2013) Jérôme Galon et al. JOURNAL OF PATHOLOGY
- Innate and adaptive immune cells in the tumor microenvironment
- (2013) Thomas F Gajewski et al. NATURE IMMUNOLOGY
- From antimicrobial to anticancer peptides. A review
- (2013) Diana Gaspar et al. Frontiers in Microbiology
- Toward integrative cancer immunotherapy: targeting the tumor microenvironment
- (2012) Leisha A Emens et al. Journal of Translational Medicine
- The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
- (2011) M J M Gooden et al. BRITISH JOURNAL OF CANCER
- Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
- (2011) Peter Friedl et al. CELL
- TNM Staging in Colorectal Cancer: T Is for T Cell and M Is for Memory
- (2011) Elizabeth K. Broussard et al. JOURNAL OF CLINICAL ONCOLOGY
- On the selectivity and efficacy of defense peptides with respect to cancer cells
- (2011) Frederick Harris et al. MEDICINAL RESEARCH REVIEWS
- Cationic amphiphilic peptides with cancer-selective toxicity
- (2009) Frank Schweizer EUROPEAN JOURNAL OF PHARMACOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started